Company Overview

Vir Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing treatments and preventive therapies for serious infectious diseases and other high-burden conditions. The company operates primarily in the biotechnology and biopharmaceutical industries, with a strategy centered on leveraging immunologic insights to develop monoclonal antibodies, T-cell–based therapies, vaccines, and other immune-mediated technologies. Vir’s principal areas of focus have included hepatitis delta virus (HDV), chronic hepatitis B virus (HBV), influenza, HIV, and pandemic preparedness initiatives. The company generates revenue primarily through collaboration agreements, licensing arrangements, and research partnerships, while its product portfolio remains largely in clinical development stages.

Vir was founded in 2016 by biotechnology investor and entrepreneur Robert Nelsen and immunologist Herbert “Skip” Virgin. Since inception, the company has expanded through acquisitions, licensing transactions, and strategic collaborations with major pharmaceutical and biotechnology companies. Vir became widely recognized during the COVID-19 pandemic through its collaboration with GlaxoSmithKline on sotrovimab, a monoclonal antibody developed for SARS‑CoV‑2. The company’s positioning has emphasized integrating immunology expertise with advanced platform technologies and partnerships to address infectious diseases with significant unmet medical need.

Business Operations

Vir Biotechnology organizes its operations around infectious disease research and therapeutic development programs. Its core pipeline has included programs targeting HBV and HDV through T-cell and antibody-based approaches, as well as broader antiviral and vaccine-related initiatives. The company has controlled or licensed multiple technology platforms, including monoclonal antibody engineering, siRNA-related approaches through partnerships, and T-cell receptor technologies. Revenue has historically been derived from collaboration agreements, milestone payments, and licensing activities rather than broad commercial product sales.

The company maintains operations primarily in the United States, with research, clinical, and partnership activities extending internationally. Vir has collaborated with several major pharmaceutical organizations, including GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and other biotechnology partners tied to antiviral development and immunologic technologies. Through these relationships, Vir has accessed manufacturing capabilities, clinical infrastructure, and commercialization support while continuing to develop internally managed clinical programs. Public disclosures in SEC filings indicate that collaboration revenue and research funding remain significant contributors to operating activity.

Strategic Position & Investments

Vir Biotechnology’s strategy has focused on building a differentiated infectious disease platform supported by partnerships, internal R&D investment, and selective acquisitions or licensing arrangements. The company has emphasized advancing therapies capable of inducing functional cures or long-duration immune control in chronic viral infections such as HBV and HDV. Vir has also invested in next-generation antibody technologies and immune-system–focused therapeutics designed to address viral escape mechanisms and emerging pathogens.

A notable strategic event was the company’s partnership with GlaxoSmithKline, which accelerated development and commercialization efforts related to COVID‑19 therapeutics. Vir has also expanded capabilities through transactions involving antibody discovery technologies and immune-platform assets. The company continues to invest in clinical-stage programs and translational immunology research while evaluating opportunities in pandemic preparedness and broader antiviral therapeutics. Data regarding future commercial positioning remains dependent on clinical trial outcomes and regulatory developments disclosed in public filings.

Geographic Footprint

Vir Biotechnology is headquartered in San Francisco, California, and operates primarily in the United States, while maintaining a global clinical and partnership footprint. The company’s clinical studies and collaborations have involved sites and partners across North America, Europe, and parts of Asia-Pacific, reflecting the international nature of infectious disease research and regulatory development.

Through partnerships with multinational pharmaceutical companies and global research institutions, Vir has established operational and scientific influence beyond its direct physical footprint. Its therapeutic programs target diseases with worldwide prevalence, including HBV, HDV, influenza, and pandemic-related viral threats. International collaboration has been central to Vir’s clinical development, manufacturing access, and regulatory engagement strategy.

Leadership & Governance

Vir Biotechnology’s leadership team combines experience in biotechnology research, pharmaceutical development, immunology, and corporate finance. The company was founded with strong scientific leadership from Herbert “Skip” Virgin and strategic backing from biotechnology-focused investment organizations. Vir’s governance structure reflects a research-driven approach with emphasis on long-term innovation in infectious disease therapeutics.

Key executives and leaders have included:

• Marianne De Backer – Chief Executive Officer
• Herbert “Skip” Virgin – Co-Founder and Former Chief Scientific Officer
• Mark Eisner – Executive Vice President, Chief Medical Officer
• Jaqui Schmidt – Executive Vice President and Chief Financial Officer
• Robert Nelsen – Co-Founder and Board Chair

Leadership communications in public filings and investor materials have consistently emphasized scientific rigor, strategic partnerships, and long-term investment in immune-based therapeutics targeting serious infectious diseases. Data regarding leadership composition and titles is based on available public company disclosures and may change with subsequent corporate announcements.